CH 64 SYSTEMIC LUPUS ERYTHEMATOSUS QUESTIONS WITH COMPLETE ANSWERS.

CH 64 SYSTEMIC LUPUS
ERYTHEMATOSUS QUESTIONS WITH
COMPLETE ANSWERS
Which ddpatient ddshould ddthe ddnurse ddexpect ddto ddbe ddat ddthe ddhighest ddrisk ddfor
ddsystemic ddlupus dderythematosus dd(SLE)?


a. ddA dd24-year-old ddwhite ddfemale
b. ddA dd55-year-old ddHispanic ddmale
c. ddA dd28-year-old ddAsian ddAmerican ddfemale
d. ddA dd30-year-old ddAfrican ddAmerican ddmale dd- ddAnswer ddANS: ddC

SLE ddis dda ddcomplex dddisorder ddaffecting dd250,000 ddpeople ddin ddthe ddUnited
ddStates, ddwith ddwomen dd6 ddto dd10 ddtimes ddmore ddlikely ddto dddevelop ddthis dddisorder
ddthan ddmen. ddThe ddAsian ddAmerican ddfemale ddis ddat dda ddhigher ddrisk ddfor ddSLE
ddthan ddthe ddAfrican ddAmerican ddand ddHispanic ddmales ddbecause ddshe ddis ddfemale.
ddShe ddis ddalso ddat dda ddhigher ddrisk ddthan ddthe ddwhite ddfemale ddbecause ddwhite
ddfemales ddare ddat dda ddlower ddrisk ddthan ddAsian ddAmerican ddfemales.


Survival ddin ddpatients ddwith ddsystemic ddlupus dderythematosus dd(SLE) ddis dddependent
ddon ddwhich ddfactors? ddSelect ddall ddthat ddapply.


a. ddAge
b. ddSex
c. ddRace
d. ddComorbid ddconditions
e. ddNonsteroidal ddantiinflammatory dddrug dd(NSAID) dduse dd- ddAnswer ddANS: ddA ddB
ddC ddD


A ddmajor ddchallenge ddin ddSLE ddtreatment ddis ddmanaging ddactive dddisease ddwhile
ddpreventing ddcomplications. ddSurvival ddappears ddto ddbe ddinfluenced ddby ddseveral
ddfactors, ddincluding ddcomorbid ddconditions, ddrace, ddage, ddsex, ddand ddsocioeconomic
ddstatus. ddNSAID dduse ddis dda ddmainstay ddof dddrug ddtherapy ddin ddthe ddtreatment ddof
ddarthritis ddassociated ddwith ddSLE, ddnot ddan ddinfluencing ddfactor ddfor ddsurvival.

,Which dddiagnostic ddlaboratory ddstudies ddare ddutilized ddin ddthe ddevaluation ddof
ddsystemic ddlupus dderythematosus dd(SLE)? ddSelect ddall ddthat ddapply.


a. ddUrinalysis
b. ddChest ddx-ray
c. ddSerum ddcomplement
d. ddElectrocardiogram dd(ECG)
e. ddComplete ddblood ddcell ddcount dd(CBC) dd- ddAnswer ddANS: ddA ddC ddE

A ddCBC, ddserum ddcomplement, ddand ddurinalysis ddare ddall dddiagnostic ddlaboratory
ddstudies ddused ddto ddevaluate ddSLE. ddA ddchest ddx-ray ddand ddan ddECG ddare dduseful
ddin dddiagnostic ddassessment ddof ddSLE, ddbut ddthese ddare ddnot ddlaboratory ddstudies.


To dddiagnose dda ddpatient ddwith ddsystemic ddlupus dderythematosus dd(SLE), ddthe
ddpatient ddmust ddmeet ddhow ddmany ddof ddthe dddistinct ddcriteria ddeither
ddsimultaneously ddor ddin ddsequential ddevaluation?


a ddThree
b. ddFour
c. ddFive
d. ddSix dd- ddAnswer ddANS: ddB

Patients ddare dddiagnosed ddwith ddSLE ddif ddthey ddhave ddfour ddof ddthe ddcriteria ddfor
ddthe dddisease ddeither ddsimultaneously ddor ddin ddsequential ddobservation ddsince
ddthere ddis ddno ddspecific dddiagnostic ddtest ddfor ddSLE. ddMeeting ddthree ddis ddtoo ddfew,
ddand ddmeeting ddfive ddor ddsix ddis ddsubsumed ddin ddmeeting ddfour.


A ddcommon dddiagnostic ddfeature ddof ddsystemic ddlupus dderythematosus dd(SLE) ddis
ddthe ddmalar ddrash, ddwhich ddis ddcharacterized ddby ddwhat ddfeatures?


a. ddPainless ddoral ddulcerations

b. ddSkin ddrash ddas ddan ddunusual ddreaction ddto ddlight

c. ddFixed dderythema, ddflat ddor ddraised, ddusually ddin dda ddbutterfly ddpattern

d. ddRaised ddpatches ddwith ddscaling ddfollicular ddplugging ddand ddscarring ddin ddolder
ddlesions dd- ddAnswer ddANS: ddC


A ddmalar ddrash ddis dda ddfixed dderythema ddthat ddis ddeither ddflat ddor ddraised, ddalso
ddknown ddas dda ddbutterfly ddrash. ddRaised ddpatches ddwith ddscaling ddfollicular
ddplugging ddis ddassociated ddwith dddiscoid ddrash, ddwhich ddis ddalso ddfound ddin ddSLE;
ddPhotosensitivity ddis dda ddskin ddrash ddas ddan ddunusual ddreaction ddto ddlight ddwhich
ddcan ddbe ddfound ddin ddSLE. ddPainless ddoral ddulcerations ddare ddalso dda ddhallmark ddof
ddSLE ddbut ddare ddnot dda ddfeature ddof ddthe ddmalar ddrash.

, What ddmarker ddis ddfound ddin dda ddmajority ddof ddpatients dddiagnosed ddwith ddsystemic
ddlupus dderythematosus dd(SLE)?


a. ddC-reactive ddprotein dd(CRP)

b. ddAntinuclear ddantibody dd(ANA)

c. ddCarcinoembryonic ddantigen dd(CEA)

d. ddErythrocyte ddsedimentation ddrate dd(ESR) dd- ddAnswer ddANS: ddB

Of ddthose dddiagnosed ddwith ddSLE, dd97% ddhave ddANA ddin ddtheir ddblood. ddESR ddand
ddCRP ddare ddmarkers ddof ddinflammation ddthat ddmay ddbe ddused ddto ddmonitor
dddisease ddactivity ddand ddeffectiveness ddof ddtherapy. ddCEA ddis dda ddblood ddmarker
ddthat ddis dduseful ddin dddiagnosing ddsome ddcancers; ddit ddis ddunrelated ddto ddSLE.


What ddenvironmental ddfactors ddare ddbelieved ddto ddcontribute ddto ddthe ddoccurrence
ddof ddsystemic ddlupus dderythematosus dd(SLE)? ddSelect ddall ddthat ddapply.


a. ddStress

b. ddHormones

c. ddViral ddinfections

d. ddUltraviolet dd(UV) ddlight ddexposure

e. ddExposure ddto ddchemicals ddand ddtoxins dd- ddAnswer ddANS: ddA ddC ddD ddE

Environmental ddexposure ddto ddsome ddchemicals ddor ddtoxins, ddUV ddlight, ddviral
ddinfections, ddand ddstress ddcan ddstimulate ddimmune ddhyperactivity ddwhich ddmay
ddtrigger ddSLE. ddHormones ddare ddalso ddknown ddto ddplay dda ddrole ddin ddthe ddetiology
ddof ddSLE, ddbut ddthey ddare ddnot ddan ddenvironmental ddfactor.


A ddpatient ddwith ddsystemic ddlupus dderythematosus ddhas dddeveloped ddosteoporosis
ddrelated ddto ddthe dddisease ddprocess. ddWhich dddrug ddtherapy dddoes ddthe ddnurse
ddanticipate ddthe ddpatient ddwill ddbe ddprescribed?


a. ddTacrolimus
b. ddPrasterone
c. ddAzathioprine
d. ddPimecrolimus dd- ddAnswer ddANS: ddB

Prasterone ddis dda ddhormone ddused ddto ddtreat ddlupus-induced ddosteoporosis.
ddTacrolimus ddand ddpimecrolimus ddare ddused ddto ddtreat ddintegumentary ddsymptoms
ddof ddbutterfly ddrash ddand dddiscoid ddlesion ddin ddsystemic ddlupus dderythematosus